FHD-286 |
| Katalog-Nr.GC64821 |
FHD-286 ist ein BRG1/BRM-ATPase-Inhibitor zur Behandlung von BAF-bedingten Erkrankungen wie akuter myeloischer LeukÄmie.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2671128-05-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
FHD-286 is a BRG1/BRM ATPase inhibitor for the treatment of BAF-related disorders such as acute myeloid leukemia.
[1]. Centore, Richard C. et al. Preparation of BRG1/BRM inhibitors for treating cancer. US20220079940 A1.
Review for FHD-286
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
Review for FHD-286
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *